Kinase News and Research

RSS

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Ambit Biosciences Corporation announced today the presentation of two posters presenting the results of preclinical studies evaluating AC220 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

8 Dec 2009

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

Incyte Corporation announced this morning that INCB18424 (also referred to as INCB018424), its selective, orally available janus kinase (JAK) inhibitor, will be the subject of three oral presentations at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans.

7 Dec 2009

SU2C awards $9.68 million to support high-risk cancer research

Stand Up To Cancer (SU2C) announced today that it is awarding $9.68 million to support high-risk/high-reward cancer research conducted by 13 young scientists.

7 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

Critical enzyme activity provides new insight into heart disease mechanisms

Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of heart cells.

5 Dec 2009

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

4 Dec 2009

Pfizer to present study findings from its expanded breast cancer portfolio

Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13.

4 Dec 2009

Preclinical data of Curis' HSP 90 inhibitor published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics.

4 Dec 2009

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.

3 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.

1 Dec 2009

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

ChemGenex Pharmaceuticals Limited announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana.

1 Dec 2009

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell.

26 Nov 2009

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML).

25 Nov 2009

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

ARIAD Pharmaceuticals, Inc. today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009.

23 Nov 2009

Winship-led team identifies a way to exploit cancer cells' taste for glucose

The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.

23 Nov 2009

Ligon Discovery raises $1 million

Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced that it has raised $1M in seed financing led by incTANK Ventures. The company will use the capital to complete its initial discovery campaign that will screen over 100 high-value disease protein targets. With this investment, incTANK Ventures General Partner Christian Bailey joins the board.

19 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Kinase News and Research

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

SU2C awards $9.68 million to support high-risk cancer research

New treatment options for leukemia and myeloproliferative disorders introduced

Critical enzyme activity provides new insight into heart disease mechanisms

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Pfizer to present study findings from its expanded breast cancer portfolio

Preclinical data of Curis' HSP 90 inhibitor published

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

New data demonstrating the strength of Novartis' hematology portfolio to be presented

DiaMedica to acquire all issued and outstanding shares of Sanomune

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

Winship-led team identifies a way to exploit cancer cells' taste for glucose

Ligon Discovery raises $1 million

New biomarkers can predict patients' response to certain drugs

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News